Nordic Nanovector: Provisional head

CTO Lars Nieba has taken over as interim CEO at Nordic Nanovectors after Eduardo Bravo’s sudden departure.

Nieba joined Nordic Nanovector in 2019 from Bayer AG where he served in various operational and strategic roles. Most recently, Nieba was responsible for driving Bayer’s Chemistry, Manufacturing and Controls (CMC) strategy for biologicals. Before joining Bayer in 2016, he held various leadership roles at F. Hoffmann-La Roche Ltd. Prior to that, Nieba worked for Cytos Biotechnology where he served as Head of Therapeutic Vaccine Research.

Dr Nieba gained a PhD from the Max-Planck-Institute for Biochemistry, München and Institute for Biochemistry at the University of Zürich, and an Executive MBA from the University of St. Gallen, Switzerland.